Klassic Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 3 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.68 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit 1027.37%
(FY 2023)
- Ebitda 115.31%
(FY 2023)
- Net Worth 408.90%
(FY 2023)
- Total Assets 85.05%
(FY 2023)
About Klassic Pharmaceuticals India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.68 Cr.
Vinay Soni, Abhimanyu Soni, and Khushivinder Kaur serve as directors at the Company.
- CIN/LLPIN
U51909PB2021PTC054778
- Company No.
054778
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Jalandhar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Klassic Pharmaceuticals India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Soni  | Director | 26-Nov-2021 | Current |
| Abhimanyu Soni | Director | 10-Jun-2023 | Current |
| Khushivinder Kaur | Director | 26-Nov-2021 | Current |
Financial Performance of Klassic Pharmaceuticals India.
Klassic Pharmaceuticals India Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 1027.37% increase in profit. The company's net worth Soared by an impressive increase of 408.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Klassic Pharmaceuticals India?
In 2023, Klassic Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fruchtbar Lifesciences Private LimitedActive 1 year 5 monthsVinay Soni, Abhimanyu Soni and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Apr 2022 | ₹4.68 Cr | Open |
How Many Employees Work at Klassic Pharmaceuticals India?
Klassic Pharmaceuticals India has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Klassic Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Klassic Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
